¼¼°èÀÇ À¯Àüü ¾Ï ÆÐ³Î ¹× ÇÁ·ÎÆÄÀϸµ ½ÃÀå º¸°í¼­(2025³â)
Genomic Cancer Panel And Profiling Global Market Report 2025
»óǰÄÚµå : 1760539
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,217,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,987,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,756,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

À¯Àüü ¾Ï ÆÐ³Î ¹× ÇÁ·ÎÆÄÀϸµ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̸ç 2029³â±îÁö 8.7%ÀÇ CAGR·Î 143¾ï 7,000¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¾×ü »ý°Ë Àû¿ë È®´ë, Á¶±â ¹ß°ß¿¡ ´ëÇÑ È°¿ë È®´ë, ¸ÂÃãÇü Ä¡·áÀÇ Áö¼ÓÀûÀÎ ¼ºÀå, µ¿¹ÝÁø´Ü¾à¹° ½ÂÀÎ Áõ°¡ µîÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â À¯Àüü µ¥ÀÌÅÍ ÇØ¼®À» À§ÇÑ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕ, ¸ÖƼ¿À¹Í½º Á¢±Ù¹ý °³¹ß, Ŭ¶ó¿ìµå ±â¹Ý À¯Àüü µ¥ÀÌÅÍ ÀúÀå ¹× ºÐ¼®, ÀüÀÚÀǹ«±â·Ï°úÀÇ ÅëÇÕ, Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®(NGS) Ç÷§ÆûÀÇ È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¾Ï ¹ßº´·ü Áõ°¡´Â À¯Àüü ¾Ï ÆÐ³Î ¹× ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ÏÀº ü³» ºñÁ¤»óÀûÀÎ ¼¼Æ÷ÀÇ ÅëÁ¦ÇÒ ¼ö ¾ø´Â Áõ½Ä°ú È®»êÀ» Ư¡À¸·Î ÇÏ´Â Áúº´ÀÔ´Ï´Ù. ¾Ï ¹ßº´·üÀÇ Áõ°¡´Â ÁÖ·Î °í·ÉÈ­ µîÀÇ ¿äÀο¡ ±âÀÎÇϸç, °í·ÉÈ­·Î ÀÎÇØ ¼ö¸íÀÌ ±æ¾îÁö¸é ¾Ï ¹ß»ý À§ÇèÀÌ Áõ°¡ÇÕ´Ï´Ù. À¯Àüü ¾Ï ÆÐ³Î ¹× ÇÁ·ÎÆÄÀϸµÀº À¯ÀüÀÚ º¯ÀÌ ¹× ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ´Â µ¥ »ç¿ëµÇ¾î °³ÀÎÈ­µÈ Ä¡·á °èȹÀ» ¿ëÀÌÇÏ°Ô Çϰí Á¶±â ¹ß°ß ¹× Áúº´ ¸ð´ÏÅ͸µÀ» °³¼±ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù ¹Ì±¹¾ÏÇùȸ´Â 2022³â Àü ¼¼°èÀûÀ¸·Î ¾à 2,000¸¸ ¸íÀÌ »õ·Î ¾Ï Áø´ÜÀ» ¹Þ°í 970¸¸ ¸íÀÌ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. Àα¸ Áõ°¡¿¡ µû¶ó Àü ¼¼°è ¾Ï ȯÀÚ ¼ö´Â 2050³â±îÁö 3,500¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µû¶ó¼­ ¾Ï ¹ßº´·üÀÇ Áõ°¡´Â À¯Àüü ¾Ï ÆÐ³Î ¹× ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

À¯Àüü ¾Ï ÆÐ³Î ¹× ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ¾Ï Áø´ÜÀÇ Á¤È®¼º, ½Å¼Ó¼º, Æ÷°ý¼ºÀ» ³ôÀ̱â À§ÇØ Â÷¼¼´ë ½ÃÄö½Ì µî ±â¼ú Çõ½Å¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®±â´Â À¯ÀüÀÚ º¯ÀÌ ¹× ±âŸ À¯Àüü Ư¼ºÀ» ÆÄ¾ÇÇϱâ À§ÇØ À¯Àü ¹°ÁúÀ» ½Å¼ÓÇÏ°í ³ôÀº 󸮷®À¸·Î ºÐ¼®ÇÒ ¼ö Àִ ÷´Ü DNA ¿°±â¼­¿­ ºÐ¼® ±â¼úÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 4¿ù ³×´ú¶õµåÀÇ »ý¸í°øÇÐ ±â¾÷ QIAGEN N.V.´Â Â÷¼¼´ë ½ÃÄö¼­¿ëÀ¸·Î ¼³°èµÈ QIAseq ÆÐ³ÎÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÆÐ³ÎÀº 700°³ ÀÌ»óÀÇ À¯ÀüÀÚ¸¦ ºÐ¼®ÇÏ¿© Á¾ÇÕÀûÀÎ À¯Àüü ÇÁ·ÎÆÄÀϸµÀ» °¡´ÉÇÏ°Ô Çϸç, ¾Ï Áø´Ü ¹× Ä¡·á Àü·«À» °³¼±Çϱâ À§ÇÑ ¿¬±¸ ¹× ÀÓ»ó Àû¿ëÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Genomic cancer panel and profiling is a molecular diagnostic technique that simultaneously analyzes multiple genes to detect genetic mutations, alterations, or biomarkers linked to cancer. Its primary purpose is to guide personalized treatment decisions, predict disease progression, and enhance cancer diagnosis and monitoring.

The main tissue testing types in the genomic cancer panel and profiling market are solid tissue testing and liquid tissue testing. Solid tissue testing involves analyzing samples from solid tumors or organs to identify genetic mutations, biomarkers, or disease characteristics. Various technologies are employed in this process, including next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others. Cancer panels used in this testing include both single-gene and multi-gene panels. These tests are applied in clinical and research settings, serving end users such as hospitals, research and academic institutes, clinical and diagnostic laboratories, among others.

The genomic cancer panel and profiling market research report is one of a series of new reports from The Business Research Company that provides genomic cancer panel and profiling market statistics, including the genomic cancer panel and profiling industry global market size, regional shares, competitors with the genomic cancer panel and profiling market share, detailed genomic cancer panel and profiling market segments, market trends, and opportunities, and any further data you may need to thrive in the genomic cancer panel and profiling industry. This genomic cancer panel and profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genomic cancer panel and profiling market size has grown strongly in recent years. It will grow from $9.47 billion in 2024 to $10.31 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. Growth during the historic period can be attributed to the rising global cancer burden, increased use in clinical trials, expansion of diagnostic infrastructure, growing awareness of genetic testing, and increased government and research funding.

The genomic cancer panel and profiling market size is expected to see strong growth in the next few years. It will grow to $14.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. Growth in the forecast period is expected to be driven by the expansion of liquid biopsy applications, growing use in early detection, the continued growth in tailored therapies, and an increase in companion diagnostics approvals. Key trends in the forecast period include the integration of AI and machine learning for genomic data interpretation, the development of multi-omics approaches, cloud-based genomic data storage and analysis, integration with electronic health records, and the expansion of next-generation sequencing (NGS) platforms.

The increasing incidence of cancer is expected to drive the growth of the genomic cancer panel and profiling market. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising cancer incidence is primarily due to factors such as an aging population, which increases the risk of cancer as people live longer. Genomic cancer panels and profiling are used to identify genetic mutations and biomarkers, facilitating personalized treatment plans and improving early detection and disease monitoring. For example, in January 2024, the American Cancer Society reported that approximately 20 million new cancer cases were diagnosed globally in 2022, resulting in 9.7 million deaths. With population growth, the global cancer burden is projected to rise to 35 million cases by 2050. Therefore, the increasing incidence of cancer will drive the growth of the genomic cancer panel and profiling market.

Major companies in the genomic cancer panel and profiling market are focusing on technological innovations, such as next-generation sequencers, which enhance the accuracy, speed, and comprehensiveness of cancer diagnostics. Next-generation sequencers are advanced DNA sequencing technologies that allow for rapid, high-throughput analysis of genetic material to identify mutations and other genomic features. For instance, in April 2025, QIAGEN N.V., a Netherlands-based biotechnology company, launched QIAseq panels designed for next-generation sequencers. These panels enable comprehensive genomic profiling by analyzing over 700 genes, targeting both research and clinical applications to improve cancer diagnostics and treatment strategies.

In June 2023, Quest Diagnostics, a US-based clinical laboratory company, acquired Haystack Oncology, a biotech firm specializing in liquid biopsy technologies for early cancer detection and monitoring. The acquisition expands Quest Diagnostics' capabilities in liquid biopsy and cancer detection, enhancing its genomic testing offerings.

Major players in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., and Predictive Oncology Inc.

North America was the largest region in the genomic cancer panel and profiling market in 2024. The regions covered in genomic cancer panel and profiling report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the genomic cancer panel and profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genomic cancer panel and profiling market consists of revenues earned by entities by providing services such as genetic mutation analysis, companion diagnostic testing, cancer risk assessment, and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic cancer panel and profiling market also includes sales of targeted gene panels, companion diagnostic kits, sequencing platforms and instruments, bioinformatics software, and analysis tools. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Genomic Cancer Panel And Profiling Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on genomic cancer panel and profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for genomic cancer panel and profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genomic cancer panel and profiling market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Genomic Cancer Panel And Profiling Market Characteristics

3. Genomic Cancer Panel And Profiling Market Trends And Strategies

4. Genomic Cancer Panel And Profiling Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Genomic Cancer Panel And Profiling Growth Analysis And Strategic Analysis Framework

6. Genomic Cancer Panel And Profiling Market Segmentation

7. Genomic Cancer Panel And Profiling Market Regional And Country Analysis

8. Asia-Pacific Genomic Cancer Panel And Profiling Market

9. China Genomic Cancer Panel And Profiling Market

10. India Genomic Cancer Panel And Profiling Market

11. Japan Genomic Cancer Panel And Profiling Market

12. Australia Genomic Cancer Panel And Profiling Market

13. Indonesia Genomic Cancer Panel And Profiling Market

14. South Korea Genomic Cancer Panel And Profiling Market

15. Western Europe Genomic Cancer Panel And Profiling Market

16. UK Genomic Cancer Panel And Profiling Market

17. Germany Genomic Cancer Panel And Profiling Market

18. France Genomic Cancer Panel And Profiling Market

19. Italy Genomic Cancer Panel And Profiling Market

20. Spain Genomic Cancer Panel And Profiling Market

21. Eastern Europe Genomic Cancer Panel And Profiling Market

22. Russia Genomic Cancer Panel And Profiling Market

23. North America Genomic Cancer Panel And Profiling Market

24. USA Genomic Cancer Panel And Profiling Market

25. Canada Genomic Cancer Panel And Profiling Market

26. South America Genomic Cancer Panel And Profiling Market

27. Brazil Genomic Cancer Panel And Profiling Market

28. Middle East Genomic Cancer Panel And Profiling Market

29. Africa Genomic Cancer Panel And Profiling Market

30. Genomic Cancer Panel And Profiling Market Competitive Landscape And Company Profiles

31. Genomic Cancer Panel And Profiling Market Other Major And Innovative Companies

32. Global Genomic Cancer Panel And Profiling Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Genomic Cancer Panel And Profiling Market

34. Recent Developments In The Genomic Cancer Panel And Profiling Market

35. Genomic Cancer Panel And Profiling Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â